Search - tctmd.com

Displaying 1 - 20 of 123

Sort: Relevancy | Date

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

News Conference News TCT 2025

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

November 03, 2025

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

News Conference News TCT 2025

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

October 27, 2025

Renewed Questions About Safety of Paclitaxel Devices in PAD: SWEDEPAD

News Conference News ESC 2025

Renewed Questions About Safety of Paclitaxel Devices in PAD: SWEDEPAD

September 05, 2025

AQUATIC: More Than 6 Months After PCI, Don’t Use Aspirin With OAC

News Conference News ESC 2025

AQUATIC: More Than 6 Months After PCI, Don’t Use Aspirin With OAC

September 01, 2025

No Benefit to Routine CT Angiography After Left Main PCI: PULSE

News Conference News ESC 2025

No Benefit to Routine CT Angiography After Left Main PCI: PULSE

Michael O'Riordan

August 31, 2025

Short DAPT Safe in ACS With No Ischemic Penalty: 4D-ACS

News Conference News EuroPCR 2025

Short DAPT Safe in ACS With No Ischemic Penalty: 4D-ACS

May 30, 2025

Complete Revascularization in STEMI Still Superior at 10 Years: DANAMI-3-PRIMULTI

News Conference News EuroPCR 2025

Complete Revascularization in STEMI Still Superior at 10 Years: DANAMI-3-PRIMULTI

Michael O'Riordan

May 20, 2025

Paclitaxel or Sirolimus: New PAD Studies Shed Light on Choices

News Conference News CX Symposium 2025

Paclitaxel or Sirolimus: New PAD Studies Shed Light on Choices

April 23, 2025

AGENT IDE: DCB Performance for In-Stent Restenosis Lasts Out to 2 Years

News Conference News CRT 2025

AGENT IDE: DCB Performance for In-Stent Restenosis Lasts Out to 2 Years

March 10, 2025

Amputations Still Avoided With Flow-Diverting Therapy for CLTI at 2 Years: PROMISE II

News Conference News VIVA 2024

Amputations Still Avoided With Flow-Diverting Therapy for CLTI at 2 Years: PROMISE II

November 06, 2024

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

News Conference News VIVA 2024

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

November 05, 2024

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

News Conference News TCT 2024

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

October 29, 2024

DCB Outdo Noncompliant Balloons in Simple Bifurcation Side Branches: DCB-BIF

News Conference News TCT 2024

DCB Outdo Noncompliant Balloons in Simple Bifurcation Side Branches: DCB-BIF

October 28, 2024

ESC’s 2024 CCS Guidelines Embrace New Data, Smooth Old Tensions

News Conference News ESC 2024

ESC’s 2024 CCS Guidelines Embrace New Data, Smooth Old Tensions

Michael O'Riordan

September 17, 2024

‘Unlocking’ Scaffold Matches DES in Wide Range of PCI Patients, Including ACS

News Conference News ESC 2024

‘Unlocking’ Scaffold Matches DES in Wide Range of PCI Patients, Including ACS

Michael O'Riordan

September 09, 2024

Complete Revascularization Better for Older STEMI Patients: Meta-analysis

News Conference News ESC 2024

Complete Revascularization Better for Older STEMI Patients: Meta-analysis

September 04, 2024

OCCUPI: OCT Guidance Improves Outcomes in Complex PCI

News Conference News ESC 2024

OCCUPI: OCT Guidance Improves Outcomes in Complex PCI

September 03, 2024

Full AGENT IDE Results Affirm Benefits of DCB for In-Stent Restenosis

News Conference News CRT 2024

Full AGENT IDE Results Affirm Benefits of DCB for In-Stent Restenosis

March 09, 2024

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

News Conference News AHA 2023

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

Michael O'Riordan

November 11, 2023

Sirolimus- and Paclitaxel-Coated Balloons Well-Matched for In-Stent Restenosis

News Conference News TCT 2023

Sirolimus- and Paclitaxel-Coated Balloons Well-Matched for In-Stent Restenosis

November 02, 2023

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.